Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

sEphB4-HSA - VasGene Therapeutics

Next Previous
Search
Drug Profile

sEphB4-HSA - VasGene Therapeutics

Alternative Names: EphB4-HSA; EphB4-Human Serum Albumin; Human Serum Albumin-EphB4 conjugate; Recombinant EphB4-HSA Fusion Protein; Vas 01

Latest Information Update: 18 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VasGene Therapeutics
  • Developer National Cancer Institute (USA); University of Southern California; VasGene Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Bladder cancer; Chronic myelomonocytic leukaemia; Head and neck cancer; Kaposi's sarcoma; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • No development reported Leukaemia; Renal cancer

Most Recent Events

  • 10 Jul 2024 Vasgene Therapeutics plans a phase II/III trial for Bladder cancer (Combination therapy) and Urogenital cancer (Combination therapy, Metastatic disease) (IV, Infusion) in September 2024 (NCT06493552)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 25 Oct 2022 Vasgene Therapeutics and University of Colorado completes a phase-I clinical trial in Head and neck cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT04091867)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top